Neuronetics
From Wikipedia, the free encyclopedia
| Neuronetics, Inc. | |
|---|---|
 |
|
| Type | Private |
| Founded | 2003 |
| Headquarters | Malvern, PA, United States |
| Key people | Bruce Shook, President & CEO Mark Bausinger, CFO Mark Demitrack MD, Chief Medical Officer Mark Riehl, Product Development & Operations Peter Anastasiou, VP Marketing Judy Ways, Ph.D., VP Regulatory Affairs & Quality Assurance Stanford Miller, VP Health Policy & Access Jim Breidenstein, VP Sales & Customer Service |
| Industry | Medical Devices and Medical Technology |
| Products | NeuroStar TMS Therapy System |
| Employees | Approximately 30 |
| Website | www.Neuronetics.com |
Neuronetics is a privately-held company developing non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology. Their NeuroStar TMS Therapy System was developed for treating major depression in patients who have not responded to, or are intolerant of, drug therapy.
Neuronetics was founded within The Innovation Factory, an Atlanta, GA-based medical technology incubator. The Company has raised significant venture capital on the strength of its unique intellectual property portfolio and experienced management team. Neuronetics’ investors include well-known life-sciences firms such as Quaker BioVentures, Three Arch Partners, Investor Growth Capital, Onset Ventures, Interwest Partners, KBL Healthcare Ventures and Accuitive Medical Ventures.[1]
Contents |
[edit] Products
Neuronetics' first product, the NeuroStar TMS Therapy System is designed to non-invasively stimulate the brain using highly focused MRI-strength magnetic fields, or Transcranial Magnetic Stimulation (TMS). NeuroStar delivers therapy that is highly targeted, involving a key brain region that is known to be dysfunctional in patients suffering from depression. NeuroStar TMS Therapy is prescribed by a psychiatrist and is delivered in an outpatient setting. The patient sits in the chair and undergoes 40-minute sessions over the course of three to six weeks.[2]
[edit] Approval Status
NeuroStar is currently pending FDA approval for the treatment of depression. The FDA’s final decision regarding approval of the NeuroStar TMS Therapy System is expected in 2008.
